ReviewJournal of Alzheimer's disease : JAD2008
Antioxidants in central nervous system diseases: preclinical promise and translational challenges.
Review in Journal of Alzheimer's disease : JAD, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 4 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- A Systematic Review of the Protective Actions of Cat's Whiskers (Misai Kucing) on the Central Nervous System.Frontiers in pharmacology · 2020Pooled it
- Vitamin E for Alzheimer's dementia and mild cognitive impairment.The Cochrane database of systematic reviews · 2017Pooled it
- Vitamin E for Alzheimer's dementia and mild cognitive impairment.The Cochrane database of systematic reviews · 2017Pooled it
- Vitamin E for Alzheimer's dementia and mild cognitive impairment.The Cochrane database of systematic reviews · 2012Pooled it
- NLRP3 Inflammasome Activation in Oxidative Stress: A Key Mechanism Driving Neuroinflammation.Neuroimmunomodulation · 2026Review
- In vivo, in silico effects of sakuranetin as a multi-target nutraceutical against PTZ-induced seizures via GABA restoration and BDNF/TrkB activation.Scientific reports · 2025Article
- Aldose Reductase Inhibition byMolecules (Basel, Switzerland) · 2025Article
- Stigmasterol Alleviates Levodopa-Induced Dyskinesia in 6-OHDA-Induced Parkinsonian Rats.Neurochemical research · 2025Article
- Review
- Blood Catalase, Superoxide Dismutase, and Glutathione Peroxidase Activities in Alcohol- and Opioid-Addicted Patients.Medicina (Kaunas, Lithuania) · 2025Article
- Editorial: The role of natural and synthetic antioxidants in the therapeutic targeting of oxidative stress.Frontiers in molecular biosciences · 2025Article
- Alzheimer's Disease: A Review of Pathology, Current Treatments, and the Potential Therapeutic Effect of Decreasing Oxidative Stress by Combined Vitamin D and l-Cysteine Supplementation.Antioxidants & redox signaling · 2024Review
- Caffeic Acid Phenethyl Ester (CAPE): Biosynthesis, Derivatives and Formulations with Neuroprotective Activities.Antioxidants (Basel, Switzerland) · 2023Review
- The Role of Diet as a Modulator of the Inflammatory Process in the Neurological Diseases.Nutrients · 2023Review
- Alzheimer's and Parkinson's disease therapies in the clinic.Bioengineering & translational medicine · 2023Review
- Methylene blue: a controversial diagnostic acid and medication?Toxicology research · 2022Review
- Oxidative Stress in Tauopathies: From Cause to Therapy.Antioxidants (Basel, Switzerland) · 2022Review
- Exploring multifunctional antioxidants as potential agents for management of neurological disorders.Environmental science and pollution research international · 2022Review
- Metabolic correlates of late midlife cognitive outcomes: findings from the 1946 British Birth Cohort.Brain communications · 2022Article
- Polydatin protects neuronal cells from hydrogen peroxide damage by activating CREB/Ngb signaling.Molecular medicine reports · 2022Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Oxidative damage is strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and stroke (brain ischemia/reperfusion injury). The availability of transgenic and toxin-inducible models of these conditions has facilitated the preclinical evaluation of putative antioxidant agents ranging from prototypic natural antioxidants such as vitamin E (alpha-tocopherol) to sophisticated synthetic free radical traps and catalytic oxidants. Literature review shows that antioxidant therapies have enjoyed general success in preclinical studies across disparate animal models, but little benefit in human intervention studies or clinical trials. Recent high-profile failures of vitamin E trials in Parkinson's disease, and nitrone therapies in stroke, have diminished enthusiasm to pursue antioxidant neuroprotectants in the clinic. The translational disappointment of antioxidants likely arises from a combination of factors including failure to understand the drug candidate's mechanism of action in relationship to human disease, and failure to conduct preclinical studies using concentration and time parameters relevant to the clinical setting. This review discusses the rationale for using antioxidants in the prophylaxis or mitigation of human neurodiseases, with a critical discussion regarding ways in which future preclinical studies may be adjusted to offer more predictive value in selecting agents for translation into human trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.